share_log

Ayala Pharmaceuticals Analyst Ratings

Benzinga ·  Nov 16, 2023 14:11
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/16/2023 Ladenburg Thalmann Downgrades Buy → Neutral
05/30/2023 450.74% Ladenburg Thalmann → $4 Upgrades Neutral → Buy
12/18/2018 HC Wainwright & Co. Downgrades Buy → Neutral

What is the target price for Ayala Pharmaceuticals (ADXS)?

The latest price target for Ayala Pharmaceuticals (OTCQX: ADXS) was reported by Ladenburg Thalmann on November 16, 2023. The analyst firm set a price target for $0.00 expecting ADXS to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Ayala Pharmaceuticals (ADXS)?

The latest analyst rating for Ayala Pharmaceuticals (OTCQX: ADXS) was provided by Ladenburg Thalmann, and Ayala Pharmaceuticals downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for Ayala Pharmaceuticals (ADXS)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ayala Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ayala Pharmaceuticals was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.

Is the Analyst Rating Ayala Pharmaceuticals (ADXS) correct?

While ratings are subjective and will change, the latest Ayala Pharmaceuticals (ADXS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Ayala Pharmaceuticals (ADXS) is trading at is $0.73, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment